Literature DB >> 30635160

A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis.

Maya R Jacobson1, Jeremy J Watts2, Isabelle Boileau3, Junchao Tong4, Romina Mizrahi5.   

Abstract

Cannabis, the most widely used illicit drug worldwide, produces psychoactive effects through its component cannabinoids, which act on the endocannabinoid system. Research on how cannabinoid exposure affects the endocannabinoid system is limited. Substantial evidence indicates cannabis use as a risk factor for psychosis, and the mechanism(s) by which this is occurring is/are currently unknown. Here, we conduct the first review of the effects of exogenous cannabinoids on the endocannabinoid system in humans with and without psychotic disorders. The most well established finding is the down-regulation of cannabinoid CB1 receptors (CB1R) after chronic and recent cannabis exposure, but it remains uncertain whether this effect is present in cannabis users with schizophrenia. We highlight where cannabis exposure affects the endocannabinoid system in a pattern that may mirror what is seen in psychosis, and how further research can push this field forward. In these times of changing cannabis legislation, research highlighting the biological effects of cannabinoids is greatly needed.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Addiction; Cannabinoid; Cannabis; Endocannabinoid; Review; Schizophrenia

Mesh:

Substances:

Year:  2019        PMID: 30635160     DOI: 10.1016/j.euroneuro.2018.12.014

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  8 in total

1.  Impact of cyclooxygenase-2 inhibition on cannabis withdrawal and circulating endocannabinoids in daily cannabis smokers.

Authors:  Margaret Haney; Gillinder Bedi; Ziva D Cooper; Evan S Herrmann; Stephanie Collins Reed; Richard W Foltin; Philip J Kingsley; Lawrence J Marnett; Sachin Patel
Journal:  Addict Biol       Date:  2022-07       Impact factor: 4.093

2.  Cannabis Exposure Decreases Need for Blood Pressure Support During General Anesthesia in Orthopedic Trauma Surgery.

Authors:  Brent G Yeung; Michael W Ma; John A Scolaro; Ariana M Nelson
Journal:  Cannabis Cannabinoid Res       Date:  2021-07-05

Review 3.  Endocannabinoid-Mediated Neuromodulation in the Olfactory Bulb: Functional and Therapeutic Significance.

Authors:  Naina Bhatia-Dey; Thomas Heinbockel
Journal:  Int J Mol Sci       Date:  2020-04-19       Impact factor: 5.923

Review 4.  The Origin and Biomedical Relevance of Cannabigerol.

Authors:  Anna Jastrząb; Iwona Jarocka-Karpowicz; Elżbieta Skrzydlewska
Journal:  Int J Mol Sci       Date:  2022-07-19       Impact factor: 6.208

5.  Effects of super-class cannabis terpenes beta-caryophyllene and alpha-pinene on zebrafish behavioural biomarkers.

Authors:  Andréa Johnson; Alycia Stewart; Ismaeel El-Hakim; Trevor J Hamilton
Journal:  Sci Rep       Date:  2022-10-14       Impact factor: 4.996

Review 6.  Endocannabinoid system in psychotic and mood disorders, a review of human studies.

Authors:  Ranjini Garani; Jeremy J Watts; Romina Mizrahi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-09-06       Impact factor: 5.067

Review 7.  Endocannabinoid-mediated neuromodulation in the main olfactory bulb at the interface of environmental stimuli and central neural processing.

Authors:  Thomas Heinbockel; Naina Bhatia-Dey; Vonnie D C Shields
Journal:  Eur J Neurosci       Date:  2021-04-02       Impact factor: 3.698

Review 8.  Cannabidiol (CBD) as a novel treatment in the early phases of psychosis.

Authors:  Edward Chesney; Dominic Oliver; Philip McGuire
Journal:  Psychopharmacology (Berl)       Date:  2021-07-13       Impact factor: 4.415

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.